The North America Cell Therapy Technologies Market is witnessing robust growth owing to advancements in cell-based research and a rising prevalence of chronic diseases. The market size was valued at USD 4,950 Million in 2025 and is expected to reach USD 16,430 Million by 2035, expanding at a CAGR of 11.5% from 2024 to 2035. Key market players, including Thermo Fisher Scientific, Lonza Group, and Sartorius AG, are launching novel solutions to support the scalability, quality, and safety of cell therapies.
The economic impact of tariffs on "North America Cell Therapy Technologies Market".
Market Growth Drivers
Rising Prevalence of Chronic and Genetic Diseases: Increased incidence of cancers, autoimmune, and genetic disorders in North America continues to drive demand for cell therapy technologies. With cell therapies offering targeted and personalized treatment options, the region has seen accelerated investments and research activities. For example, Novartis has expanded its CAR-T therapy manufacturing facility in New Jersey to support increasing therapy adoption, demonstrating the growing clinical and commercial need for advanced cell therapy platforms.
Advancements in Cell Processing Technology: New technologies that improve cell isolation, purification, and expansion have significantly boosted market growth. Automation solutions by companies such as Thermo Fisher Scientific are minimizing manual errors and enhancing consistency in cell product manufacturing. This continuous innovation in manufacturing practices accelerates successful commercialization and ensures the generation of higher-efficacy therapies for diverse patient populations.
Market Trends
Integration of Artificial Intelligence in Cell Therapy Development: AI-powered platforms are being increasingly adopted to optimize and speed up cell therapy research and development. Companies like Cellino Biotech are leveraging machine learning for automated cell manufacturing and quality control, resulting in increased reproducibility and reduced costs. The trend highlights the move toward more data-driven, efficient, and scalable production lines in the sector.
Expansion of Allogeneic Cell Therapies: There is a notable shift from autologous (patient-derived) to allogeneic (donor-derived) therapies due to advantages such as off-the-shelf availability and lower costs. Companies including Allogene Therapeutics are pioneering the development and clinical trials of allogeneic CAR-T therapies, making cell therapies more accessible and broadening their market reach in North America.
Market Opportunity
Strategic Collaborations and Acquisitions: Opportunities for growth exist through partnerships and acquisitions between biotech companies and large-scale pharmaceutical firms. For example, Thermo Fisher’s acquisition of Brammer Bio enables expanded capabilities in viral vector production crucial for advanced cell therapies.
Development of Next-Generation Cell Therapy Platforms: Companies investing in novel gene-editing technologies, such as CRISPR-based cell therapies, can tap into unmet clinical needs and capture significant market share. Precision BioSciences is leading efforts in this domain by advancing off-the-shelf CAR-T therapies.
North America Cell Therapy Technologies Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates a steady uptick in North America's cell therapy technologies market over the forecast period. Starting from USD 2,100 Million in 2020, the market shows consistent yearly growth driven by rising cell therapy approvals, increased investment in R&D, and strong adoption across oncology and regenerative medicine. By 2025, the revenue reaches USD 4,950 Million, and this momentum continues, culminating at USD 16,430 Million by 2035. The upward trend signifies expanding clinical applications, increasing commercial launches, and enhanced manufacturing capabilities, confirming the region’s pivotal role in driving cell therapy advancements globally.
North America Cell Therapy Technologies Market by Regions Share (%), 2025
In 2025, the United States dominates the North America Cell Therapy Technologies Market, occupying a major share of 78%, credited to its advanced healthcare infrastructure, significant R&D investment, and a large number of active clinical trials. Canada follows with 15%, supported by robust government initiatives and rising biopharma collaborations. Mexico and the Rest of North America (covering Caribbean and Central America) hold comparatively smaller shares—5% and 2%, respectively—attributed to growing but still nascent cell therapy research activities. The chart emphasizes the U.S.'s leadership but also highlights gradual growth in other regional markets.
Recent Developments (Past 6 Months)
In March 2024, Lonza Group announced the launch of a next-generation cell therapy manufacturing platform designed to accelerate clinical-to-commercial scale transition. This integrated solution covers isolation, expansion, and formulation steps, focusing on cost efficiency and regulatory compliance for both autologous and allogeneic therapies in North America.
April 2024 saw Thermo Fisher Scientific unveil a suite of automated closed-system instruments for GMP-compliant cell processing. The new platform reduces contamination risk and streamlines workflow, enhancing consistency in cell therapy production. Early collaborations with bluebird bio have resulted in accelerated timelines for launch-ready cell products.
In May 2024, Allogene Therapeutics gained the FDA’s Fast Track designation for its allogeneic CAR-T therapy, ALLO-501A, targeting lymphomas. This regulatory milestone paves the way for faster clinical development and underlines the momentum building in the off-the-shelf cell therapy segment across North America.
Press Releases